US Stock Insider Trading | Roivant Sciences Disclosed 15 Insider Transactions on February 13

K-LinePoet · 2026-03-17T03:29:48+00:00

Roivant Sciences disclosed multiple insider transactions on February 13, 2026, with director Gold Daniel Allen and shareholder QVT Financial LP executing substantial stock sales, with total transaction value exceeding $200 million. Roivant is committed to improving healthcare by advancing drug development through innovative approaches.

K-LinePoet

2026-03-17 03:29:48

Abstract generation in progress

On February 13, 2026, Roivant Sciences (ROIV) disclosed 15 insider transactions. Director Gold Daniel Allen sold 425,000 shares.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
2026-02-13	Director	Gold Daniel Allen, MANCHESTER KEITH S	2026-02-12	Sell	550,000	26.76	14,778,000
2026-02-13	Shareholder	QVT Financial LP	2026-02-11	Sell	425,000	26.67	11,334,750
2026-02-13	Director	Gold Daniel Allen, MANCHESTER KEITH S	2026-02-11	Sell	850,000	26.67	22,669,500
2026-02-13	Director	Gold Daniel Allen, MANCHESTER KEITH S	2026-02-12	Sell	300,000	26.72	8,016,000
2026-02-13	Shareholder	QVT Financial LP	2026-02-13	Sell	150,800	26.49	3,994,300
2026-02-13	Shareholder	QVT Financial LP	2026-02-13	Sell	225,000	26.50	5,962,500
2026-02-13	Director	Gold Daniel Allen, MANCHESTER KEITH S	2026-02-13	Sell	450,000	26.50	11,925,000
2026-02-13	Director	Gold Daniel Allen, MANCHESTER KEITH S	2026-02-13	Sell	301,600	26.49	7,988,500
2026-02-13	Shareholder	QVT Financial LP	2026-02-12	Sell	275,000	26.76	7,359,000
2026-02-13	Shareholder	QVT Financial LP	2026-02-12	Sell	150,000	26.72	4,008,000

[Company Profile]

Roivant Sciences Ltd. is a company incorporated in Bermuda on July 6, 2020. Roivant’s mission is to improve healthcare for patients by viewing every inefficiency as an opportunity. Roivant accelerates the development of transformative drugs by creatively building technology and cultivating talent, launching “Vants”—flexible and focused biopharmaceutical and health technology companies—through the Roivant platform.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes